A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Safety, Tolerability, Immunogenicity and Efficacy of a Variant-Adapted BNT162b2 Vaccine in Healthy Participants 50 through 64 years of age.